Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Release

Auris Medical Announces AAO-HNSF Annual Meeting Activities

Auris Medical AG
Posted on: 13 Sep 16
  • Presentation of safety data from Keyzilen TM program and symposium on tinnitus pharmacotherapy set for September 18 and 19

ZUG, Switzerland, September 13, 2016 -- Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology, today announced that safety data from the Keyzilen TM (AM-101) program will be presented at the 2016 Annual Meeting & OTO EXPO SM of the American Academy of Otolaryngology-Head and Neck Surgery Foundation (AAO-HNSF). In addition, the company will host a corporate symposium featuring experts in the field of tinnitus research. [1]

Hinrich Staecker, MD, PhD, Professor of Otolaryngology at the University of Kansas Medical Center, will deliver an oral presentation titled "Safety of Repeated Intratympanic AM-101 in Acute Inner Ear Tinnitus" on September 18, 2016, at 11:40 am PDT at the San Diego Convention Center in Room 31A.

On September 19, 2016, at 6 pm PDT, Auris Medical will host a corporate symposium titled "Advancing Pharmacotherapy for Tinnitus." The event will include presentations by Marlies Knipper, PhD, on the development of peripheral and central tinnitus; Lawrence R. Lustig, MD, on the history of intratympanic drug therapy; James A. Henry, PhD, on the clinical use of the Tinnitus Functional Index; and Hinrich Staecker, MD, PhD, on the clinical development of the NMDA receptor antagonist AM-101. The symposium will take place at the Hilton Bayfront Hotel in San Diego, and a webcast will be available in the Investor Relations section of the Auris Medical website at www.aurismedical.com following the event.

About Auris Medical

Auris Medical is a Swiss biopharmaceutical company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology. The Company is currently focusing on the Phase 3 development of treatments for acute inner ear tinnitus (Keyzilen TM ; AM-101) and for acute inner ear hearing loss (AM-111) by way of intratympanic administration with biocompatible gel formulations. In addition, Auris Medical is pursuing early-stage research and development projects. The Company was founded in 2003 and is headquartered in Zug, Switzerland. The shares of the parent company Auris Medical Holding AG trade on the NASDAQ Global Market under the symbol "EARS."

[1] This event is not part of the official AAO-HNSF 2016 Annual Meeting & OTO EXPO SM .

Forward-looking Statements

This press release may contain statements that constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are statements other than historical fact and may include statements that address future operating, financial or business performance or Auris Medical's strategies or expectations. In some cases, you can identify these statements by forward-looking words such as "may," "might," "will," "should," "expects," "plans," "anticipates," "believes," "estimates," "predicts," "projects," "potential," "outlook" or "continue," and other comparable terminology. Forward-looking statements are based on management's current expectations and beliefs and involve significant risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those contemplated by these statements. These risks and uncertainties include, but are not limited to, the timing and conduct of clinical trials of Auris Medical's product candidates, the clinical utility of Auris Medical's product candidates, the timing or likelihood of regulatory filings and approvals, Auris Medical's intellectual property position and Auris Medical's financial position, including the impact of any future acquisitions, dispositions, partnerships, license transactions or changes to Auris Medical's capital structure, including future securities offerings. These risks and uncertainties also include, but are not limited to, those described under the caption "Risk Factors" in Auris Medical's Annual Report on Form 20-F and future filings with the Securities and Exchange Commission. Forward-looking statements speak only as of the date they are made, and Auris Medical does not undertake any obligation to update them in light of new information, future developments or otherwise, except as may be required under applicable law. All forward-looking statements are qualified in their entirety by this cautionary statement.

Contact: Cindy McGee, Head of Investor Relations and Corporate Communications, +41 61 201 1350, investors@aurismedical.com

Media contact: David Schull, Russo Partners, 1-858-717-2310, david.schull@russopartnersllc.com



This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Auris Medical AG via GlobeNewswire
HUG#2041757
GlobeNewswire
globenewswire.com

Last updated on: 14/09/2016

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.